Asifa Sarfraz , Irfa Chaudhary , Fizza Arshad , Muhammad Shehroz , Asia Perveen , Umar Nishan , Abid Ali , Riaz Ullah , Abdelaaty A. Shahat , Aqal Zaman , Mohibullah Shah
{"title":"通过免疫信息学方法设计基于肽的亨德拉病毒疫苗。","authors":"Asifa Sarfraz , Irfa Chaudhary , Fizza Arshad , Muhammad Shehroz , Asia Perveen , Umar Nishan , Abid Ali , Riaz Ullah , Abdelaaty A. Shahat , Aqal Zaman , Mohibullah Shah","doi":"10.1016/j.vetimm.2024.110869","DOIUrl":null,"url":null,"abstract":"<div><div>The Hendra virus (HeV) has resulted in epidemics of respiratory and neurological illnesses in animals. Humans have contracted diseases with high fatality rates as a result of infected domestic animals, but effective vaccinations and therapies are currently not available against HeV. Herein, we analyzed the proteome of HeV and constructed an effective and innovative multi-epitope vaccine using immunoinformatics techniques. The vaccine construct was generated, targeting one matrix protein, with the help of the five selected B and T cell epitopes, linkers, and adjuvants and evaluated for their immunogenic properties. <em>In-silico</em> analysis revealed that the epitopes were able to interact with immune receptors and had high antigenic qualities. The post-translational modifications (PTMs), globular, disordered regions, and the active site of the vaccine were predicted, and the strong interactions between the vaccine and Toll-like receptor 5 were observed in molecular docking, indicating their potential significance in the immune response to the designed vaccine. The structural and dynamic stability of the vaccine were ensured by the molecular dynamic simulations. The results of the immune simulations indicated that the designed vaccine might activate B and T cells, which produce high levels of antibodies and cytokines to fight HeV infection. The developed vaccine is useful due to its non-toxicity, non-sensitization, good immunogenicity, non-allergic, and antigenic properties, accessed by various tools; however, experimental verification is needed to confirm the findings of the current study.</div></div>","PeriodicalId":23511,"journal":{"name":"Veterinary immunology and immunopathology","volume":"280 ","pages":"Article 110869"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peptide-based vaccine design against Hendra virus through immunoinformatics approach\",\"authors\":\"Asifa Sarfraz , Irfa Chaudhary , Fizza Arshad , Muhammad Shehroz , Asia Perveen , Umar Nishan , Abid Ali , Riaz Ullah , Abdelaaty A. Shahat , Aqal Zaman , Mohibullah Shah\",\"doi\":\"10.1016/j.vetimm.2024.110869\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The Hendra virus (HeV) has resulted in epidemics of respiratory and neurological illnesses in animals. Humans have contracted diseases with high fatality rates as a result of infected domestic animals, but effective vaccinations and therapies are currently not available against HeV. Herein, we analyzed the proteome of HeV and constructed an effective and innovative multi-epitope vaccine using immunoinformatics techniques. The vaccine construct was generated, targeting one matrix protein, with the help of the five selected B and T cell epitopes, linkers, and adjuvants and evaluated for their immunogenic properties. <em>In-silico</em> analysis revealed that the epitopes were able to interact with immune receptors and had high antigenic qualities. The post-translational modifications (PTMs), globular, disordered regions, and the active site of the vaccine were predicted, and the strong interactions between the vaccine and Toll-like receptor 5 were observed in molecular docking, indicating their potential significance in the immune response to the designed vaccine. The structural and dynamic stability of the vaccine were ensured by the molecular dynamic simulations. The results of the immune simulations indicated that the designed vaccine might activate B and T cells, which produce high levels of antibodies and cytokines to fight HeV infection. The developed vaccine is useful due to its non-toxicity, non-sensitization, good immunogenicity, non-allergic, and antigenic properties, accessed by various tools; however, experimental verification is needed to confirm the findings of the current study.</div></div>\",\"PeriodicalId\":23511,\"journal\":{\"name\":\"Veterinary immunology and immunopathology\",\"volume\":\"280 \",\"pages\":\"Article 110869\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Veterinary immunology and immunopathology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0165242724001557\",\"RegionNum\":3,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary immunology and immunopathology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165242724001557","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Peptide-based vaccine design against Hendra virus through immunoinformatics approach
The Hendra virus (HeV) has resulted in epidemics of respiratory and neurological illnesses in animals. Humans have contracted diseases with high fatality rates as a result of infected domestic animals, but effective vaccinations and therapies are currently not available against HeV. Herein, we analyzed the proteome of HeV and constructed an effective and innovative multi-epitope vaccine using immunoinformatics techniques. The vaccine construct was generated, targeting one matrix protein, with the help of the five selected B and T cell epitopes, linkers, and adjuvants and evaluated for their immunogenic properties. In-silico analysis revealed that the epitopes were able to interact with immune receptors and had high antigenic qualities. The post-translational modifications (PTMs), globular, disordered regions, and the active site of the vaccine were predicted, and the strong interactions between the vaccine and Toll-like receptor 5 were observed in molecular docking, indicating their potential significance in the immune response to the designed vaccine. The structural and dynamic stability of the vaccine were ensured by the molecular dynamic simulations. The results of the immune simulations indicated that the designed vaccine might activate B and T cells, which produce high levels of antibodies and cytokines to fight HeV infection. The developed vaccine is useful due to its non-toxicity, non-sensitization, good immunogenicity, non-allergic, and antigenic properties, accessed by various tools; however, experimental verification is needed to confirm the findings of the current study.
期刊介绍:
The journal reports basic, comparative and clinical immunology as they pertain to the animal species designated here: livestock, poultry, and fish species that are major food animals and companion animals such as cats, dogs, horses and camels, and wildlife species that act as reservoirs for food, companion or human infectious diseases, or as models for human disease.
Rodent models of infectious diseases that are of importance in the animal species indicated above,when the disease requires a level of containment that is not readily available for larger animal experimentation (ABSL3), will be considered. Papers on rabbits, lizards, guinea pigs, badgers, armadillos, elephants, antelope, and buffalo will be reviewed if the research advances our fundamental understanding of immunology, or if they act as a reservoir of infectious disease for the primary animal species designated above, or for humans. Manuscripts employing other species will be reviewed if justified as fitting into the categories above.
The following topics are appropriate: biology of cells and mechanisms of the immune system, immunochemistry, immunodeficiencies, immunodiagnosis, immunogenetics, immunopathology, immunology of infectious disease and tumors, immunoprophylaxis including vaccine development and delivery, immunological aspects of pregnancy including passive immunity, autoimmuity, neuroimmunology, and transplanatation immunology. Manuscripts that describe new genes and development of tools such as monoclonal antibodies are also of interest when part of a larger biological study. Studies employing extracts or constituents (plant extracts, feed additives or microbiome) must be sufficiently defined to be reproduced in other laboratories and also provide evidence for possible mechanisms and not simply show an effect on the immune system.